Proactive Investors - Run By Investors For Investors

Horizon Discovery hails role in colorectal cancer diagnostic trial

Horizon's reference standards helped establish the performance specifications of the assay for the unnamed customer
picture of cell
The diagnostic is for colorectal cancer

Genetic biomarkers supplied by Horizon Discovery Group PLC’s (LON:HZD) were used as the reference standard in a recent US pre-market approval application for a colorectal cancer diagnostic tool, it said today.

In the development and subsequent clinical trial, Horizon's materials helped establish the performance specifications of the assay and were used for development and quality control of the molecular assays.

Horizon has expertise in the identification of  colorectal cancer through its co –founder Professor Alberto Bardelli and Dr. Sabine Tejpar (a scientific board member) who first made the link between K-RAS mutations and resistance to standad care drugs in up to 65% of colon cancer sufferers.

The company carried on the work through the COLTHERES consortium, a four year €6 million funded  collaboration of EU-based clinical centers and translational researchers, which identified additional biomarkers in the 30-40% of patients who are resistant to Cetuximab, a therapeutic for the treatment of advanced colorectal cancer. 

Darrin Disley, Horizon’s chief executive said: We are pleased that our Reference Standards have proven such a valuable component of this seminal clinical trial and FDA approval with one of the world's leading players in the genomics and diagnostics market.


“We are currently supporting many similar trials and products and look forward to making an impact on the lives of patients through our products." 

View full HZD profile View Profile

Horizon Discovery Group PLC Timeline

Related Articles

scientist in a lab
April 12 2019
Danish giant Novo Nordisk recently signed up to use its NDD platform, and bosses expect more collaboration deals in the coming months
Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours
technician's in a lab clean-room
March 12 2019
The Maryland company is seeing revenue surge through an expansion of contract manufacturing services, particularly in the area of CAR T-cell therapies

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use